(ARNA) - buyArena Pharmaceuticals prepared for conference call at 8:00 EDT Friday on second pivotal trial of its experimental obesity drug lorcaserin.-------Signup and get instant entry alerts for...
#6: ARNA Stock News : Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
- Late-Breaking Data from Pivotal BLOOM Trial Presented at the
American Diabetes Association's 69th Scientific Sessions Expand on
Previously Announced Positive Top-Line Results -
NEW...
#5: ARNA Stock News : Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions
- Late-Breaking Abstract Accepted -
SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today
that a late-breaking abstract of its...
#4: ARNA Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today it has obtained an equity financing commitment of up to $50 milli
SAN DIEGO, March 23
/PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA stock)
announced today it has obtained an equity financing commitment of up to
$50 million from Azimuth...
SAN DIEGO, Nov. 20 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it is scheduled to provide an overview of the company, including its clinical...
SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
CIBC World Markets 18th Annual Healthcare...
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA Forum Stocks) announced today that the company is scheduled to present at Citigroup's Global Healthcare Conference on May 24, 2007 at 11:00 a.m. Eastern...
